SK5352003A3 - Bis-heterocyclic compounds with antitumour and chemosensitising activity - Google Patents
Bis-heterocyclic compounds with antitumour and chemosensitising activity Download PDFInfo
- Publication number
- SK5352003A3 SK5352003A3 SK535-2003A SK5352003A SK5352003A3 SK 5352003 A3 SK5352003 A3 SK 5352003A3 SK 5352003 A SK5352003 A SK 5352003A SK 5352003 A3 SK5352003 A3 SK 5352003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- compound
- aromatic
- tumor
- formula
- atra
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 11
- 230000000694 effects Effects 0.000 title description 37
- 150000001875 compounds Chemical class 0.000 claims description 158
- 238000002360 preparation method Methods 0.000 claims description 67
- -1 N-benzylindol-3-yl Chemical group 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 31
- 230000003034 chemosensitisation Effects 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 21
- 239000002246 antineoplastic agent Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 10
- 230000007170 pathology Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 206010059866 Drug resistance Diseases 0.000 claims description 8
- 229940041181 antineoplastic drug Drugs 0.000 claims description 8
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims description 7
- QUCOKMOPNOTIHP-UHFFFAOYSA-N 1-benzyl-3-[1-(1-benzylindol-3-yl)but-1-enyl]indole Chemical compound C=1N(CC=2C=CC=CC=2)C2=CC=CC=C2C=1C(=CCC)C(C1=CC=CC=C11)=CN1CC1=CC=CC=C1 QUCOKMOPNOTIHP-UHFFFAOYSA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 229960001727 tretinoin Drugs 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000002458 carcinoid tumor Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000025113 myeloid leukemia Diseases 0.000 claims description 3
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 3
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 229930013930 alkaloid Natural products 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 230000002492 cytodifferentiating effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 2
- 229930014626 natural product Natural products 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000003560 cancer drug Substances 0.000 claims 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 176
- 125000003118 aryl group Chemical group 0.000 description 166
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 85
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 81
- 210000004027 cell Anatomy 0.000 description 62
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 55
- 238000000921 elemental analysis Methods 0.000 description 50
- 229910052739 hydrogen Inorganic materials 0.000 description 47
- 239000000243 solution Substances 0.000 description 43
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 35
- 238000000034 method Methods 0.000 description 33
- 239000000047 product Substances 0.000 description 33
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 28
- 230000006698 induction Effects 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 230000022131 cell cycle Effects 0.000 description 24
- 235000019439 ethyl acetate Nutrition 0.000 description 22
- 239000007787 solid Substances 0.000 description 21
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 20
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 20
- 230000011712 cell development Effects 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 229960004679 doxorubicin Drugs 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 13
- 230000024245 cell differentiation Effects 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 238000004587 chromatography analysis Methods 0.000 description 12
- 230000036457 multidrug resistance Effects 0.000 description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- 229910004298 SiO 2 Inorganic materials 0.000 description 11
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 11
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- DANQJLAJEHUMNS-UHFFFAOYSA-N 5,5-bis(5h-[1,3]dioxolo[4,5-f]indol-7-yl)pentan-1-ol Chemical compound C1=C2C(C(C=3C4=CC=5OCOC=5C=C4NC=3)CCCCO)=CNC2=CC2=C1OCO2 DANQJLAJEHUMNS-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 230000001028 anti-proliverative effect Effects 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- YJCSYGCYBUOJMI-UHFFFAOYSA-N 3-[1-(1h-indol-3-yl)butyl]-1h-indole Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)CCC)=CNC2=C1 YJCSYGCYBUOJMI-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- VLXGVOZWOVCQTE-UHFFFAOYSA-N 5,5-bis(1h-indol-3-yl)pentyl acetate Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)CCCCOC(=O)C)=CNC2=C1 VLXGVOZWOVCQTE-UHFFFAOYSA-N 0.000 description 7
- FVSAWSXPGWHDEA-UHFFFAOYSA-N 5,5-bis(1h-indol-3-yl)pentyl methanesulfonate Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)CCCCOS(=O)(=O)C)=CNC2=C1 FVSAWSXPGWHDEA-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 239000001273 butane Substances 0.000 description 7
- 239000007795 chemical reaction product Substances 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000035519 G0 Phase Effects 0.000 description 6
- 230000010190 G1 phase Effects 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 6
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 229920000137 polyphosphoric acid Polymers 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 6
- ODBSDLBIDXJGAC-UHFFFAOYSA-N 3-[1-(1h-indol-3-yl)-2-methylcyclohexyl]-1h-indole Chemical compound CC1CCCCC1(C=1C2=CC=CC=C2NC=1)C1=CNC2=CC=CC=C12 ODBSDLBIDXJGAC-UHFFFAOYSA-N 0.000 description 5
- SWXNZBVVHUOOGZ-UHFFFAOYSA-N 3-[1-(5-hydroxy-1h-indol-3-yl)butyl]-1h-indol-5-ol Chemical compound C1=C(O)C=C2C(C(C=3C4=CC(O)=CC=C4NC=3)CCC)=CNC2=C1 SWXNZBVVHUOOGZ-UHFFFAOYSA-N 0.000 description 5
- HZZBCOBMNWRHHJ-UHFFFAOYSA-N 5,5-bis(1-methylindol-3-yl)pentan-1-ol Chemical compound C12=CC=CC=C2N(C)C=C1C(CCCCO)C1=CN(C)C2=CC=CC=C12 HZZBCOBMNWRHHJ-UHFFFAOYSA-N 0.000 description 5
- RMTHYTSSFBFCDC-UHFFFAOYSA-N 5-fluoro-3-[1-(5-fluoro-1h-indol-3-yl)butyl]-1h-indole Chemical compound C1=C(F)C=C2C(C(C=3C4=CC(F)=CC=C4NC=3)CCC)=CNC2=C1 RMTHYTSSFBFCDC-UHFFFAOYSA-N 0.000 description 5
- NUAJWMRDWNRQHR-UHFFFAOYSA-N 5-nitro-3-[1-(5-nitro-1h-indol-3-yl)butyl]-1h-indole Chemical compound C1=C([N+]([O-])=O)C=C2C(C(C=3C4=CC(=CC=C4NC=3)[N+]([O-])=O)CCC)=CNC2=C1 NUAJWMRDWNRQHR-UHFFFAOYSA-N 0.000 description 5
- DWTXAWVVQNBLFJ-UHFFFAOYSA-N 7-[1-(5h-[1,3]dioxolo[4,5-f]indol-7-yl)butyl]-5h-[1,3]dioxolo[4,5-f]indole Chemical compound C1=C2C(C(C=3C4=CC=5OCOC=5C=C4NC=3)CCC)=CNC2=CC2=C1OCO2 DWTXAWVVQNBLFJ-UHFFFAOYSA-N 0.000 description 5
- 230000010757 Reduction Activity Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000001235 sensitizing effect Effects 0.000 description 5
- FGEDFUUPEMQXTJ-UHFFFAOYSA-N 3-[1-(5-amino-1h-indol-3-yl)butyl]-1h-indol-5-amine Chemical compound C1=C(N)C=C2C(C(C=3C4=CC(N)=CC=C4NC=3)CCC)=CNC2=C1 FGEDFUUPEMQXTJ-UHFFFAOYSA-N 0.000 description 4
- LCGCQDZRGRTDKV-UHFFFAOYSA-N 4,4-bis(5h-[1,3]dioxolo[4,5-f]indol-7-yl)butan-1-ol Chemical compound C1=C2C(C(C=3C4=CC=5OCOC=5C=C4NC=3)CCCO)=CNC2=CC2=C1OCO2 LCGCQDZRGRTDKV-UHFFFAOYSA-N 0.000 description 4
- HXCHORPNRVSDCD-UHFFFAOYSA-N 5h-[1,3]dioxolo[4,5-f]indole Chemical compound C1=C2OCOC2=CC2=C1NC=C2 HXCHORPNRVSDCD-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000012024 dehydrating agents Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002475 indoles Chemical class 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- KPLYYUGBRMSTPC-UHFFFAOYSA-N 3-[1-(5-amino-1h-indol-3-yl)butyl]-1h-indol-5-amine;dihydrochloride Chemical compound Cl.Cl.C1=C(N)C=C2C(C(C=3C4=CC(N)=CC=C4NC=3)CCC)=CNC2=C1 KPLYYUGBRMSTPC-UHFFFAOYSA-N 0.000 description 3
- KMFAUBANRHEOJD-UHFFFAOYSA-N 4,4-bis(1h-indol-3-yl)butan-1-ol Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)CCCO)=CNC2=C1 KMFAUBANRHEOJD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical class O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000006114 chemosensitizer Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- CMHJVZBPOHOKOC-UHFFFAOYSA-N n-[3-[1-(5-acetamido-1h-indol-3-yl)butyl]-1h-indol-5-yl]acetamide Chemical compound C1=C(NC(C)=O)C=C2C(C(C=3C4=CC(NC(C)=O)=CC=C4NC=3)CCC)=CNC2=C1 CMHJVZBPOHOKOC-UHFFFAOYSA-N 0.000 description 3
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical class ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 3
- 238000004237 preparative chromatography Methods 0.000 description 3
- 150000003233 pyrroles Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- OGXNFSOEIVPPSG-GOSISDBHSA-N (2S)-2,3-dihydroxy-1,1-diindol-3-yl-propane Natural products C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)[C@H](O)CO)=CNC2=C1 OGXNFSOEIVPPSG-GOSISDBHSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical compound NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 2
- WODGULJMZNRBMG-UHFFFAOYSA-N 2-methoxymorpholine Chemical compound COC1CNCCO1 WODGULJMZNRBMG-UHFFFAOYSA-N 0.000 description 2
- OKAMTPRCXVGTND-UHFFFAOYSA-N 2-methoxyoxolane Chemical compound COC1CCCO1 OKAMTPRCXVGTND-UHFFFAOYSA-N 0.000 description 2
- WMSGWZOURZCIBN-UHFFFAOYSA-N 4,4-bis(1h-indol-3-yl)butanoic acid Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)CCC(=O)O)=CNC2=C1 WMSGWZOURZCIBN-UHFFFAOYSA-N 0.000 description 2
- WJFKWNNLMCZLEJ-UHFFFAOYSA-N 5,5-bis(1h-indol-3-yl)pentan-1-ol Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)CCCCO)=CNC2=C1 WJFKWNNLMCZLEJ-UHFFFAOYSA-N 0.000 description 2
- LMIQERWZRIFWNZ-UHFFFAOYSA-N 5-hydroxyindole Chemical compound OC1=CC=C2NC=CC2=C1 LMIQERWZRIFWNZ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- 208000034951 Genetic Translocation Diseases 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 150000001556 benzimidazoles Chemical class 0.000 description 2
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- FGYDHYCFHBSNPE-UHFFFAOYSA-N diethyl phenylmalonate Chemical compound CCOC(=O)C(C(=O)OCC)C1=CC=CC=C1 FGYDHYCFHBSNPE-UHFFFAOYSA-N 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical group OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 208000037965 uterine sarcoma Diseases 0.000 description 2
- OQHVWBRTBGGFLM-UHFFFAOYSA-N (1-benzylimidazol-2-yl)-phenylmethanone Chemical compound C=1C=CC=CC=1C(=O)C1=NC=CN1CC1=CC=CC=C1 OQHVWBRTBGGFLM-UHFFFAOYSA-N 0.000 description 1
- OSVCNVZQCLNAHL-NMIHRBCNSA-N (2r,3r,4r,5r)-6,6-bis(1h-indol-3-yl)hexane-1,2,3,4,5-pentol Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=CNC2=C1 OSVCNVZQCLNAHL-NMIHRBCNSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- 125000006702 (C1-C18) alkyl group Chemical group 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- BBCYIQIPODTEJG-UHFFFAOYSA-N 1-benzyl-3-[1-(1-benzylindol-3-yl)butyl]indole Chemical compound C=1N(CC=2C=CC=CC=2)C2=CC=CC=C2C=1C(CCC)C(C1=CC=CC=C11)=CN1CC1=CC=CC=C1 BBCYIQIPODTEJG-UHFFFAOYSA-N 0.000 description 1
- KKKDZZRICRFGSD-UHFFFAOYSA-N 1-benzylimidazole Chemical compound C1=CN=CN1CC1=CC=CC=C1 KKKDZZRICRFGSD-UHFFFAOYSA-N 0.000 description 1
- SCUJNAJPTSOPQC-UHFFFAOYSA-N 1-methyl-3-[1-(1-methylindol-3-yl)butyl]indole Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4N(C)C=3)CCC)=CN(C)C2=C1 SCUJNAJPTSOPQC-UHFFFAOYSA-N 0.000 description 1
- LQWFBRZPLSZJNN-UHFFFAOYSA-N 1h-indole;magnesium Chemical compound [Mg].C1=CC=C2NC=CC2=C1 LQWFBRZPLSZJNN-UHFFFAOYSA-N 0.000 description 1
- AZUHIVLOSAPWDM-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)-1h-imidazole Chemical class C1=CNC(C=2NC=CN=2)=N1 AZUHIVLOSAPWDM-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- LCDPBXXTHRAUPE-UHFFFAOYSA-N 2-[1-(1h-benzimidazol-2-yl)butyl]-1h-benzimidazole Chemical compound C1=CC=C2NC(C(C=3NC4=CC=CC=C4N=3)CCC)=NC2=C1 LCDPBXXTHRAUPE-UHFFFAOYSA-N 0.000 description 1
- NZGNSNWNGXLBKL-UHFFFAOYSA-N 3-[1-(1h-indol-3-yl)tetradecyl]-1h-indole Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)CCCCCCCCCCCCC)=CNC2=C1 NZGNSNWNGXLBKL-UHFFFAOYSA-N 0.000 description 1
- BXHBDACYSOEMOG-UHFFFAOYSA-N 3-[1-(1h-pyrrolo[2,3-b]pyridin-3-yl)butyl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC=C2C(C(C=3C4=CC=CN=C4NC=3)CCC)=CNC2=N1 BXHBDACYSOEMOG-UHFFFAOYSA-N 0.000 description 1
- QLYLXCNXQVHXAL-UHFFFAOYSA-N 3-[5-bromo-1-(1h-indol-3-yl)pentyl]-1h-indole Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)CCCCBr)=CNC2=C1 QLYLXCNXQVHXAL-UHFFFAOYSA-N 0.000 description 1
- GAITWQWIFFPVBB-UHFFFAOYSA-N 4,4-bis(1h-pyrrolo[2,3-b]pyridin-3-yl)butan-1-ol Chemical compound C1=CC=C2C(C(C=3C4=CC=CN=C4NC=3)CCCO)=CNC2=N1 GAITWQWIFFPVBB-UHFFFAOYSA-N 0.000 description 1
- KZGINCJSHASHDG-UHFFFAOYSA-N 4,4-di(indol-1-yl)butanoic acid Chemical compound C1=CC2=CC=CC=C2N1C(CCC(=O)O)N1C2=CC=CC=C2C=C1 KZGINCJSHASHDG-UHFFFAOYSA-N 0.000 description 1
- QXRHGASJHJZFTR-UHFFFAOYSA-N 4-[5,5-bis(1h-indol-3-yl)pentyl]-2-[[4-[5,5-bis(1h-indol-3-yl)pentyl]morpholin-2-yl]methoxymethyl]morpholine Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)CCCCN3CC(COCC4OCCN(CCCCC(C=5C6=CC=CC=C6NC=5)C=5C6=CC=CC=C6NC=5)C4)OCC3)=CNC2=C1 QXRHGASJHJZFTR-UHFFFAOYSA-N 0.000 description 1
- VSHBABSXFHFTJN-UHFFFAOYSA-N 4-methoxymorpholine Chemical compound CON1CCOCC1 VSHBABSXFHFTJN-UHFFFAOYSA-N 0.000 description 1
- ODFFPRGJZRXNHZ-UHFFFAOYSA-N 5-fluoroindole Chemical compound FC1=CC=C2NC=CC2=C1 ODFFPRGJZRXNHZ-UHFFFAOYSA-N 0.000 description 1
- CNRGMQRNYAIBTN-UHFFFAOYSA-N 5-hydroxypentanal Chemical compound OCCCCC=O CNRGMQRNYAIBTN-UHFFFAOYSA-N 0.000 description 1
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- HLSXVABRHFKDSX-UHFFFAOYSA-M Br[Mg]c1cc2cccnc2[nH]1 Chemical compound Br[Mg]c1cc2cccnc2[nH]1 HLSXVABRHFKDSX-UHFFFAOYSA-M 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- LYAHOVOMZQDHPI-UHFFFAOYSA-N CC1=C(C(=CC=C1)C2C=CC=CO2)C3C=CC=CO3 Chemical compound CC1=C(C(=CC=C1)C2C=CC=CO2)C3C=CC=CO3 LYAHOVOMZQDHPI-UHFFFAOYSA-N 0.000 description 1
- VDZCZLDZNWNCLF-UHFFFAOYSA-N CCCC(C1C=CC=CO1)C2C=CC=CO2 Chemical compound CCCC(C1C=CC=CO1)C2C=CC=CO2 VDZCZLDZNWNCLF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 1
- 208000032464 Retinoic acid syndrome Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002634 anti-blastic effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- HFUKTZDCIMCZQU-UHFFFAOYSA-N bis(1-benzylindol-3-yl)methanone Chemical compound C=1N(CC=2C=CC=CC=2)C2=CC=CC=C2C=1C(=O)C(C1=CC=CC=C11)=CN1CC1=CC=CC=C1 HFUKTZDCIMCZQU-UHFFFAOYSA-N 0.000 description 1
- YWBNUICXGZZHMH-UHFFFAOYSA-N bis(1h-imidazol-2-yl)methanol Chemical compound N=1C=CNC=1C(O)C1=NC=CN1 YWBNUICXGZZHMH-UHFFFAOYSA-N 0.000 description 1
- HYJTUULYIOBNLS-UHFFFAOYSA-N bis(1h-indol-3-yl)methanone Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)=O)=CNC2=C1 HYJTUULYIOBNLS-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 231100000125 dermatotoxic Toxicity 0.000 description 1
- 230000000760 dermatotoxic effect Effects 0.000 description 1
- GRRSDGHTSMJICM-UHFFFAOYSA-N diethyl 2-propylpropanedioate Chemical compound CCOC(=O)C(CCC)C(=O)OCC GRRSDGHTSMJICM-UHFFFAOYSA-N 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- ZJJQLGCHEUSNRE-UHFFFAOYSA-N ethyl 5-[(5-ethoxycarbonyl-1h-pyrrol-2-yl)-phenylmethyl]-1h-pyrrole-2-carboxylate Chemical compound N1C(C(=O)OCC)=CC=C1C(C=1C=CC=CC=1)C1=CC=C(C(=O)OCC)N1 ZJJQLGCHEUSNRE-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 210000004293 human mammary gland Anatomy 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000011967 lanthanide triflate Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- RYEXTBOQKFUPOE-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].CC[CH2-] RYEXTBOQKFUPOE-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- LVCDXCQFSONNDO-UHFFFAOYSA-N n-benzylhydroxylamine Chemical compound ONCC1=CC=CC=C1 LVCDXCQFSONNDO-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 108091008726 retinoic acid receptors α Proteins 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- UHUFTBALEZWWIH-UHFFFAOYSA-N tetradecanal Chemical compound CCCCCCCCCCCCCC=O UHUFTBALEZWWIH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000RM000569A IT1317925B1 (it) | 2000-11-03 | 2000-11-03 | Bis-eterocicli ad attivita' antitumorale e chemosensibilizzante. |
| PCT/IT2001/000407 WO2002036561A1 (en) | 2000-11-03 | 2001-07-26 | Bis-heterocyclic compounds with antitumour and chemosensitising activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK5352003A3 true SK5352003A3 (en) | 2003-11-04 |
Family
ID=11454975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK535-2003A SK5352003A3 (en) | 2000-11-03 | 2001-07-26 | Bis-heterocyclic compounds with antitumour and chemosensitising activity |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7084166B2 (it) |
| EP (1) | EP1337511A1 (it) |
| JP (1) | JP2004513110A (it) |
| KR (1) | KR20030045165A (it) |
| CN (2) | CN1232518C (it) |
| AU (2) | AU2001284392B8 (it) |
| BR (1) | BR0115139A (it) |
| CA (1) | CA2427565A1 (it) |
| CZ (1) | CZ20031178A3 (it) |
| HU (1) | HUP0400584A2 (it) |
| IT (1) | IT1317925B1 (it) |
| MX (1) | MXPA03003942A (it) |
| PL (1) | PL364907A1 (it) |
| SK (1) | SK5352003A3 (it) |
| WO (1) | WO2002036561A1 (it) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060211759A1 (en) * | 2001-07-26 | 2006-09-21 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Bis-heterocyclic compounds with antitumour and chemosensitising activity |
| US7528165B2 (en) | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
| US7632955B2 (en) | 2001-12-13 | 2009-12-15 | National Health Research Institutes | Indole compounds |
| TWI317634B (en) | 2001-12-13 | 2009-12-01 | Nat Health Research Institutes | Aroyl indoles compounds |
| US6800655B2 (en) * | 2002-08-20 | 2004-10-05 | Sri International | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents |
| ATE504568T1 (de) * | 2003-08-07 | 2011-04-15 | Nat Health Research Institutes | Indol-verbindungen als inhibitoren der tubulin- polymerisation zur behandlung von angiogenesisbezogenen erkrankungen |
| DE10359462A1 (de) * | 2003-12-17 | 2005-07-28 | Westfälische Wilhelms-Universität Münster | Neuartige Platinkomplexverbindungen, Verfahren zu deren Herstellung sowie deren Verwendung für die Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Krebserkrankungen |
| US7456289B2 (en) | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
| CA2609980C (en) * | 2005-05-27 | 2015-10-13 | Queen's University At Kingston | Treatment of protein folding disorders |
| TW200716545A (en) * | 2005-06-10 | 2007-05-01 | Sigma Tau Ind Farmaceuti | Indole derivatives having anti-tumor activity |
| US9969686B2 (en) * | 2014-08-05 | 2018-05-15 | Wisconsin Alumni Research Foundation | Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them |
| JP2020530477A (ja) * | 2017-08-10 | 2020-10-22 | ザ テキサス エーアンドエム ユニヴァーシティ システム | Ｎｒ４ａ１リガンド、医薬組成物、及び関連する使用方法 |
| KR102866533B1 (ko) | 2018-04-12 | 2025-09-30 | 베르시컬러 테크놀로지스 엘엘씨 | 말라세지아-유래 화합물 및/또는 이의 화학적 유사체를 함유하는 광보호 조성물 |
| JP2021535123A (ja) | 2018-08-24 | 2021-12-16 | マイケル アインジガー， | ｍａｌａｓｓｅｚｉａ由来の化合物および／またはその化学アナログを含有する光保護性組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3738237A1 (de) * | 1987-11-11 | 1989-05-24 | Bayer Ag | Bis-indolyl-ethylen |
| JPH09506335A (ja) | 1993-09-22 | 1997-06-24 | ザ、ウェルカム、ファンデーション、リミテッド | 抗ウイルス剤としてのビス（アミノベンズイミダゾリル）アルカン |
| EP0887348A1 (en) * | 1997-06-25 | 1998-12-30 | Boehringer Mannheim Italia S.p.A. | Bis-Indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them |
-
2000
- 2000-11-03 IT IT2000RM000569A patent/IT1317925B1/it active
-
2001
- 2001-07-26 CN CNB018182933A patent/CN1232518C/zh not_active Expired - Fee Related
- 2001-07-26 CZ CZ20031178A patent/CZ20031178A3/cs unknown
- 2001-07-26 CA CA002427565A patent/CA2427565A1/en not_active Abandoned
- 2001-07-26 JP JP2002539321A patent/JP2004513110A/ja active Pending
- 2001-07-26 US US10/415,898 patent/US7084166B2/en not_active Expired - Fee Related
- 2001-07-26 PL PL01364907A patent/PL364907A1/xx not_active Application Discontinuation
- 2001-07-26 HU HU0400584A patent/HUP0400584A2/hu unknown
- 2001-07-26 KR KR10-2003-7006154A patent/KR20030045165A/ko not_active Ceased
- 2001-07-26 MX MXPA03003942A patent/MXPA03003942A/es unknown
- 2001-07-26 BR BR0115139-8A patent/BR0115139A/pt not_active IP Right Cessation
- 2001-07-26 WO PCT/IT2001/000407 patent/WO2002036561A1/en not_active Ceased
- 2001-07-26 SK SK535-2003A patent/SK5352003A3/sk not_active Application Discontinuation
- 2001-07-26 CN CNB2005100790913A patent/CN100351234C/zh not_active Expired - Fee Related
- 2001-07-26 EP EP01963372A patent/EP1337511A1/en not_active Withdrawn
- 2001-07-26 AU AU2001284392A patent/AU2001284392B8/en not_active Ceased
-
2007
- 2007-06-15 AU AU2007202805A patent/AU2007202805A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007202805A1 (en) | 2007-07-12 |
| CN1232518C (zh) | 2005-12-21 |
| CN1473150A (zh) | 2004-02-04 |
| KR20030045165A (ko) | 2003-06-09 |
| EP1337511A1 (en) | 2003-08-27 |
| HK1061243A1 (en) | 2004-09-10 |
| HUP0400584A2 (hu) | 2004-06-28 |
| PL364907A1 (en) | 2004-12-27 |
| AU8439201A (en) | 2002-05-15 |
| CN100351234C (zh) | 2007-11-28 |
| AU2001284392B2 (en) | 2007-03-08 |
| CA2427565A1 (en) | 2002-05-10 |
| US20040053987A1 (en) | 2004-03-18 |
| IT1317925B1 (it) | 2003-07-15 |
| WO2002036561A1 (en) | 2002-05-10 |
| AU2001284392B8 (en) | 2007-04-05 |
| ITRM20000569A1 (it) | 2002-05-03 |
| ITRM20000569A0 (it) | 2000-11-03 |
| CN1733722A (zh) | 2006-02-15 |
| US7084166B2 (en) | 2006-08-01 |
| CZ20031178A3 (cs) | 2003-11-12 |
| MXPA03003942A (es) | 2004-05-24 |
| JP2004513110A (ja) | 2004-04-30 |
| BR0115139A (pt) | 2003-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12338232B2 (en) | THRβ receptor agonist compound and preparation method and use thereof | |
| CN102405043B (zh) | 前神经原性化合物 | |
| TW530048B (en) | New hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and processes for their preparation | |
| CA2938280C (en) | 4-amino-imidazoquinoline compounds | |
| AU2007202805A1 (en) | Bis-heterocyclic compounds with antitumour and chemosensitising activity | |
| ES2260958T3 (es) | Ligandos selectivos del receptor 5 - ht 6. | |
| WO2016041489A1 (zh) | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法 | |
| JP2022548250A (ja) | 甲状腺ホルモン受容体ベータアゴニスト化合物 | |
| ES2303532T3 (es) | Nuevos derivados de indol y su uso como medicamentos. | |
| US6720331B2 (en) | 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents | |
| AU2003217373B2 (en) | Novel tyloindicines and related processes, pharmaceutical compositions and methods | |
| JP2585341B2 (ja) | アルキルメラトニン類 | |
| SK5342003A3 (en) | Tricyclic derivatives of indole with antiangiogenic activity | |
| JPH08509740A (ja) | カンプトテシンの水溶性誘導体 | |
| US20060211759A1 (en) | Bis-heterocyclic compounds with antitumour and chemosensitising activity | |
| RU2809040C2 (ru) | АГОНИСТ РЕЦЕПТОРОВ THRβ И СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ | |
| JP2002520412A (ja) | ５−二環式インドール化合物 | |
| HK40045137B (zh) | Smad3抑制剂 | |
| AU2002215186B2 (en) | Tricyclic derivatives of indole with antiangiogenic activity | |
| AU2001284392A1 (en) | Bis-heterocyclic compounds with antitumour and chemosensitising activity | |
| AU2002215186A1 (en) | Tricyclic derivatives of indole with antiangiogenic activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |